Testosterone supplementation for hypogonadal men by the nasal route

References

• Wang C, Swerdloff R S. Androgen replacement therapy. Ann Med 1997; 29: 365–370
   PubMed Web of Science ®Google Scholar
• Matsumoto A M. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Med Sci 2002; 57: M76–M99
   PubMed Web of Science ®Google Scholar
• Haren M T, Kim M J, Tariq S H, Wittert G A, Morley J E. Andropause: a quality-of-life issue in older males. Med Clin North Am 2006; 90: 1005–1023
   PubMed Web of Science ®Google Scholar
• Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol (Oxf) 2006; 65: 275–281
   PubMed Web of Science ®Google Scholar
• Tenover J L. The androgen-deficient aging male: current treatment options. Rev Urol 2003; 5(Suppl 1)S22–S28
   PubMedGoogle Scholar
• Jockenhovel F. Testosterone therapy – what, when and to whom. Aging Male 2004; 7: 319–324
   PubMedGoogle Scholar
• Wang C, Swerdloff R S, Irnamanesh A, Dobs A, Snyder P J, Cunningham G, Matsumoto A M, Weber T, Berman N, Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 3020–3023
   PubMedGoogle Scholar
• Swerdloff R S, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto A M, Snyder P J, Weber T, Longstreth J, Berman N. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 4500–4510
   PubMed Web of Science ®Google Scholar
• Kunz G J, Klein K O, Clemons R D, Gottschalk M E, Jones K L. Virilization of young children after topical androgen use by their parents. Pediatrics 2004; 114: 282–284
   PubMed Web of Science ®Google Scholar
• Brachet C, Vermeulen J, Heinrichs C. Children's virilization and the use of a testosterone gel by their fathers. Eur J Pediatr 2005; 164: 646–647
   PubMed Web of Science ®Google Scholar
• Spielberg T E. Abnormal testosterone levels in partners of patients using testosterone gels. J Sex Med 2005; 2: 278
   PubMedGoogle Scholar
• Merhi Z O, Santoro N. Postmenopausal virilization after spousal use of topical androgens. Fertil Steril 2007; 87: e13–e15, 976
   Google Scholar
• Bhowmick S K, Ricke T, Rettig K R. Sexual precocity in a 16-month-old boy induced by indirect topical exposure to testosterone. Clin Pediatr 2007; 46: 540–543
   PubMed Web of Science ®Google Scholar
• Morley J E. Androgens and aging. Maturitas 2001; 38: 61–71, discussion 71–73
   PubMed Web of Science ®Google Scholar
• Gooren L J, Bunch M C. Androgen replacement therapy: present and future. Drugs 2004; 64: 1861–1891
   PubMed Web of Science ®Google Scholar
• Gheorghiu M, Badiu C, Caragheorgheopol A. Clinical efficacy of the long-acting intramuscular compared to oral testosterone undecanoate in adult men with central hypogonadism. Acta Endocrinol 2008; 4: 59–73
   Google Scholar
• Bagchus W M, Hust R, Maris F, Schnabel P G, Houwing N S. Important effect of food on the bioavailability of oral testosterone undecanoate. Pharmacotherapy 2003; 23: 319–325
   PubMed Web of Science ®Google Scholar
• Haren M, Chapman I, Coates P, Morley J, Wittert G. Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age Ageing 2005; 34: 123–130
   Google Scholar
• Wittert G A, Chapman I M, Haren M T, MacKintosh S, Coates P, Morley J E. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci 2003; 58: 618–625
   PubMed Web of Science ®Google Scholar
• Houwing N S, Maris F, Schnabel P G, Bagchus W M. Pharmacokinetic study in women of three different doses of a new formulation of oral testosterone undecanoate, Andriol Testocaps. Pharmacotherapy 2003; 23: 1257–1265
   PubMedGoogle Scholar
• Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today 2002; 7: 1184–1189
   PubMed Web of Science ®Google Scholar
• Hussain A. Intranasal drug administration delivery. Adv Drug Del Rev 1998; 29: 39–49
   PubMed Web of Science ®Google Scholar
• Wattanakumtornkul S, Pinto A B, Williams D B. Intranasal hormone replacement therapy. Menopause 2003; 10: 88–98
   PubMed Web of Science ®Google Scholar
• Danner C H, Frick J. Androgen substitution with testosterone containing nasal drops. Int J Androl 1980; 3: 429–435
   PubMedGoogle Scholar
• Hussain A A, Kimura R, Hunag C H. Nasal absorption of testosterone in rats. J Pharmaceut Sci 1984; 73: 1300–1301
   PubMed Web of Science ®Google Scholar
• Hussain A A, Al-Bayatti A A, Dakkuri A, OkochI K, Hussain M A. Testosterone 17β-N,N-dimethylglycinate hydrochloride: a prodrug with a potential for nasal delivery of testosterone. J Pharmaceut Sci 2002; 91: 785–789
   PubMed Web of Science ®Google Scholar
• Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discov Today 2002; 7: 967–975
   PubMed Web of Science ®Google Scholar
• Meikle A W, Mazer N A, Moellmer J F, Stringham J D, Tolman K G, Sanders S W, Odell W D. Enhanced transdermal delivery of testosterone across non-scrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 1992; 74: 623–628
   PubMed Web of Science ®Google Scholar
• Ohdo S. Chronopharmacology focused on biological clock. Drug Metab Pharmacokinet 2007; 22: 3–14
   PubMed Web of Science ®Google Scholar
• Meikle A W, Arver S, Dobs A S, Sanders S W, Rajaram L, Mazer N A. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site – a clinical research center study. J Clin Endocrinol Metab 1996; 81: 1832–1840
   PubMed Web of Science ®Google Scholar
• Veldhuis J D, Iranmanesh A, Keenan D M. Erosion of endogenous testosterone-driven negative feedback on pulsatile luteinizing hormone secretion in healthy aging men. J Clin Endocrinol Metab 2004; 89: 5753–5761
   PubMedGoogle Scholar
• Winters S J. Diurnal rhythm of testosterone and luteinizing hormone in hypogonadal men. Androl 1991; 12: 185–190
   Google Scholar
• Liu P Y, Takahashi P Y, Roebuck P D, Iranmanesh A, Veldhuis J D. Age-specific changes in the regulation of LH-dependent testosterone secretion: assessing responsiveness to varying endogenous gonadotropin output in normal men. Am J Physiol Regul Integr Comp Physiol 2005; 289: R721–R728
   Google Scholar
• Karatsoreos I N, Silver R. Minireview: the neuroendocrinology of the suprachiasmatic nucleus as a conductor of body time in mammals. Endocrinology 2007; 148: 5640–5647
   PubMed Web of Science ®Google Scholar
• Kriegsfeld L J, Silver R. The regulation of neuroendocrine function: timing is everything (Review). Horm Behav 2006; 49: 557–574
   PubMedGoogle Scholar
• Diver M J, Imtiaz K E, Ahmad A M, Vora J P, Fraser W D. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol (Oxf) 2003; 58: 710–717
   PubMed Web of Science ®Google Scholar
• Diver M J. Analytical and physiological factors affecting the interpretation of serum testosterone concentration in men. Ann Clin Biochem 2006; 43: 3–12
   PubMed Web of Science ®Google Scholar
• Spratt D I, O'Dea L S, Schoenfeld D, Butler J, Rao P N, Crowley W F, Jr. Neuroendocrine-gonadal axis in men: frequent sampling of LH, FSH, and testosterone. Am J Physiol 1988; 254: E658–E666
   Google Scholar
• Robinson J A, Spelsberg T C. Mode of action at the cellular level with specific reference to bone cells. Estrogens and antiestrogens, R Lindsay, D W Dempster, V C Jordan. Lippincott–Raven, Philadelphia 1997; 43–62
   Google Scholar
• Tarter T H, Vaughan E D, Jr. Inhibitors of 5-alpha-reductase in the treatment of benign prostatic hyperplasia. Curr Pharm Des 2006; 12: 775–783
   PubMed Web of Science ®Google Scholar
• Bartsch G, Rittmaster R S, Klocker H. Dihydrotestosterone and the concept of 5-alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol 2002; 19: 413–425
   PubMed Web of Science ®Google Scholar
• Mooradian A D, Morley J E, Korenman S G. Biological actions of androgens. Endocrinol Rev 1987; 8: 1–28
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zheng T, Stevens R G, Zhang Y, Boyle P. Does ‘clock’ matter in prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 3–5
   PubMed Web of Science ®Google Scholar
• Alvarez J D, Hansen A, Ord T, Bebas P, Chappell P E, Giebultowicz J M, Williams C, Moss S, Sehgal A. The circadian clock protein BMAL1 is necessary for fertility and proper testosterone production in mice. J Biol Rhythms 2008; 23: 26–36
   PubMed Web of Science ®Google Scholar
• Hertoghe T. The ‘Multiple Hormone Deficiency’ theory of aging: is human senescence caused mainly by multiple hormone deficiencies. Ann NY Acad Sci 2005; 1057: 448–465
   PubMedGoogle Scholar
• Chakraborty A, Krzyzanski W, Jusko W J. Mathematical modeling of circadian cortisol concentrations using indirect response models: comparison of several methods. J Pharmacokinet Biopharm 1999; 27: 23–43
   PubMedGoogle Scholar